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Background. Pneumonia is the leading cause of death in children globally. Clinical algorithms remain suboptimal for
distinguishing severe pneumonia from other causes of respiratory distress such asmalaria or distinguishing bacterial pneu-
monia and pneumonia from others causes, such as viruses. Molecular tools could improve diagnosis and management.
Methods. Weconductedamass spectrometry–basedproteomic study to identifyandvalidatemarkersof severity in390
Gambian children with pneumonia (n = 204) and age-, sex-, and neighborhood-matched controls (n = 186). Independent
validation was conducted in 293 Kenyan children with respiratory distress (238 with pneumonia, 41 with Plasmodium fal-
ciparummalaria, and 14 with both). Predictive value was estimated by the area under the receiver operating characteristic
curve (AUC).
Results. Lipocalin 2 (Lpc-2)was the best protein biomarkerof severe pneumonia (AUC, 0.71 [95%conﬁdence interval,
.64–.79]) and highly predictive of bacteremia (78% [64%–92%]), pneumococcal bacteremia (84% [71%–98%]), and “prob-
able bacterial etiology” (91% [84%–98%]). These results were validated inKenyan childrenwith severemalaria and respira-
tory distress who also met the World Health Organization deﬁnition of pneumonia. The combination of Lpc-2 and
haptoglobin distinguished bacterial versusmalaria origin of respiratory distresswith high sensitivity and speciﬁcity inGam-
bian children (AUC, 99% [95% conﬁdence interval, 99%–100%]) and Kenyan children (82% [74%–91%]).
Conclusions. Lpc-2 and haptoglobin can help discriminate the etiology of clinically deﬁned pneumonia and could be
used to improve clinical management. These biomarkers should be further evaluated in prospective clinical studies.
Keywords. pneumonia; malaria; lipocalin-2/NGAL; respiratory infection; biomarkers.
Pneumonia is the leading cause of death in young chil-
dren globally, accounting for almost 2 million deaths
every year, mainly in developing countries [1–4]. In
The Gambia, acute lower respiratory tract infection,
principally pneumonia, is a leading cause of death in
young children [5, 6].
To reach and push beyond the United Nations’Millen-
nium Development Goal 4 for child survival, the number
of deaths caused bypneumoniamust be reduced. Thiswill
require acombinationof effectivepreventivemeasuresand
improved clinical management [7–10]. Previous studies
have shown that delayed referral is one of themost impor-
tant risk factors fordeath inchildrenwithpneumonia [11].
Therefore, current clinical algorithms to refer patients
with pneumonia to hospital are commonly based on diag-
nostic sensitivity rather than speciﬁcity. Consequently,
overreferral of pneumonia cases has been a signiﬁcant
problem with the World Health Organization (WHO)
case management strategy in some settings [12].
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Importantly, clinical criteria do not distinguish bacterial causes of
pneumonia from other causes such as viruses that do not require
antibiotic treatment.
The analysis of bioﬂuids (eg, plasma) using mass spectrome-
try–based methods has been widely adopted for biomarker dis-
covery [13–15]. Once identiﬁed and validated, proteins of
clinical value could be incorporated into rapid, point-of-care tests.
In African children, pneumonia is not the only cause of re-
spiratory distress in children. In malaria endemic areas, Plasmo-
dium falciparum infection may cause respiratory distress and
the overlap of these conditions frequently compromises the di-
agnosis and management of these patients [16–18]. In acute pe-
diatric admissions, the clinical syndrome of severe pneumonia
overlapped in 39% of severe malaria cases [19].
We conducted a study to describe the plasma proteomic sig-
nature in samples from Gambian children with severe pneumo-
nia and nonsevere pneumonia and controls. We identiﬁed and
validated biomarkers to (1) predict disease severity in children
with pneumonia, (2) predict blood culture positivity, (3) predict
probable bacterial etiology of children with pneumonia, (4)
evaluate biomarker performance to discriminate respiratory
distress caused by pneumonia or by severe malaria, and (5) pro-
vide an independent validation for the diagnostic performance
of these markers in Kenyan children.
METHODS
Study Sites and Populations Studied
The study participants were infants and children from the
Greater Banjul and Basse areas aged 2–59 months taking part
in a case-control study of childhood pneumonia and children
admitted at the Kiliﬁ District Hospital with a diagnosis of
lower respiratory tract infection (Table 1). The sites, popula-
tions studied, and clinical deﬁnitions are described in detail in
the Supplementary Methods and Supplementary Table 1.
Biomarker Discovery and Validation Studies
Plasma samples from Gambian infants and children aged 2–59
months were used for mass spectrometry–based proteomic
studies (see Supplementary Methods for details). The concen-
trations of selected proteins (C-reactive protein [CRP], vonWil-
lebrand factor [vWF], lipocalin 2 [Lp-2] and haptoglobin) were
measured with enzyme-linked immunosorbent assay (R&D
Systems), according to the manufacturer’s instructions.
Data Management and Statistical Analyses
Clinical data were collected on standardized forms and double en-
tered. Univariate and multiple logistic regression models were ﬁt-
ted for all clinical variables using disease severity and probable
bacterial etiology as dependent variables. The interaction of
independent variables was checked using the likelihood ratio
test. Data were analyzed with Stata 11 software (StataCorp).
Diagnostic Performance and Selection of Clinical Variables for
Multivariate Models
The area under the receiver operating characteristic curve
(AUC) was used to compare the sensitivity and speciﬁcity of se-
lected markers. Cutoff values were chosen based on highest sen-
sitivity and speciﬁcity to predict outcome using the roctab/
detail function (Stata 11.0). When the diagnostic performance
was assessed for >1 variable, the estimates were derived from a
logistic regression model using the selected markers or clinical
features as independent variables and the condition to diagnose
as the dependent variable. These analyses were carried out using
the lroc, lstat, and roctab/graph functions in Stata. The positive
and negative likelihood ratios have been calculated for the bio-
marker concentrations with the highest sensitivity and speciﬁc-
ity for predicting severe pneumonia.
Clinical variables and/or molecular markers were included in
themultivariatemodels if (1) the variable showeda statistically sig-
niﬁcant association (P < .05) in the univariate model and (2) the
variable had not been used as a criterion for a priori classiﬁcation.
For example, respiratory ratewas combinedwithmolecularmark-
ers to compare nonsevere and severe pneumonia because this var-
iable was not used as a criterion to separate the 2 conditions.
Ordinal univariate logistic regressionmodels usingdisease severity
coded as 0–3 (from control [0] to very severe [3]) as the dependent
variable were used to evaluate the signiﬁcance of the association
between biomarker concentration and clinical outcome.
Ethical Approval
Written informed consent was given by the parent or guardian
of each participant. Joint Gambia Government/Medical Re-
search Council (MRC) Ethical Committee approval was
obtained for both the pneumonia study (SCC/EC 1062) and
the severe malaria study (SCC/EC 630 and 670). The use of
the archived plasma samples from Kenya was approved by the
Kenya Medical Research Institute (KEMRI) Ethics Review
Committee (SSC 2280).
RESULTS
Diagnostic Performance of Clinical Features and Protein
Biomarkers to Discriminate Severe Pneumonia and Nonsevere
Pneumonia
The proteomic analysis identiﬁed 238 proteins in children with
severe pneumonia, 316 in children with nonsevere pneumonia,
and 268 in healthy controls. The difference in protein numbers
across different groups and batches was not signiﬁcantly different
(analysis of variance, P = .35). We identiﬁed 23 differentially reg-
ulated proteins (>1.5 fold) that were present in ≥2 of 3 batches
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when severe and nonsevere cases were compared and 19 when
nonsevere cases and controls were compared (Supplementary
Figure 2). Of these 42 proteins, only 8 (19%) indicated a progres-
sion pattern, namely, increasing concentration from controls to
mild to severe cases. Based on the number of peptides used to
identify these proteins and their biological relevance, Lpc-2,
CRP, and vWF were selected for further validation (Table 2).
Lpc-2, CRP, and vWF levels were signiﬁcantly higher in chil-
dren with severe pneumonia than in those with nonsevere
pneumonia (Supplementary Figure 3). Lpc-2 was the best pre-
dictor of severe pneumonia, with a sensitivity of 72.3% and a
speciﬁcity of 70.1% (AUC, 0.71 [95% conﬁdence interval [CI],
.64–.79]; Table 3). In children with Lpc-2 levels >118 ng/mL,
the odds of having severe disease increased by nearly 3-fold
(odds ratio [OR], 2.69 [95% CI, 1.08–6.69). A CRP concentra-
tion >157 µg/mL was associated with increased disease severity
(OR, 3.55 [95% CI, 1.41–8.93]), but despite its good sensitivity
to predict disease severity (70.8%), its speciﬁcity was low
(56.2%). Similarly, plasma vWF concentrations >648 mU/mL
were associated with a 5-fold increase in the odds of severe
pneumonia (OR, 5.26 [95% CI, 2.42–11.4]), with good sensitiv-
ity (87.0%) but poor speciﬁcity (41.7%; Figure 1).
The best combination of clinical and molecular markers to
predict severe pneumonia included respiratory rate, crackles,
Lpc-2, and CRP. The addition of molecular markers to the clin-
ical features had no impact on sensitivity but increased specif-
icity from 68.0% to 82.0% (Figure 1), and the effect was superior
to radiological changes (end point consolidation), crackles, and
positive blood culture combined (Supplementary Figure 6). The
sensitivity of this combination of markers increased to 94.7%
(95% CI, 88.4%–100%) in children enrolled during the dry sea-
son, possibly owing to the absence of malaria cases (Supple-
mentary Figure 4). Only 3 children of 204 (1.5%) identiﬁed as
having pneumonia had a positive malaria slide. These children
all had nonsevere pneumonia (2 enrolled during the dry season
and 1 during the rainy season).
Association of Lpc-2 With Probable Bacterial Pneumonia
Bacterial cultures were performed on 198 of 200 patients with
pneumonia (99%). Of these, 12 of 198 (6%) were positive for
true pathogens, namely Streptococcus pneumoniae (n = 10),
Staphylococcus aureus (n = 1), and Streptococcus pyogenes
(n = 1). The contamination rate was 6%. None of the clinical
variables were associated with a positive blood culture (Supple-
mentary Table 6), but children with a concentration of Lpc-2
>163 ng/mL had 9 times the odds of having a positive blood
culture with a clinically signiﬁcant isolate (OR, 9.03 [95% CI,
1.91–42.6]; Supplementary Figure 11). The plasma concentra-
tions of Lpc-2, CRP, and vWF in children with a positive
blood culture or with “end point” consolidation on their chest
radiograph (probable bacterial pneumonia) were signiﬁcantly
higher than in children with no consolidation and a low
white blood cell count (P < .01; Table 4). Lpc-2 concentrations
were strongly associated with pneumonia of probable bacterial
origin (Figure 2). The diagnostic performance of Lpc-2 was su-
perior to that of vWF or CRP. Lpc-2 showed good sensitivity
(77% [95% CI, 65.6%–89.9%]) and very high speciﬁcity
(94.4% [95% CI, 86.8%–100%]) for identifying children with
probable bacterial pneumonia. Similar results were obtained
when patients with a positive blood culture were excluded
from the analysis (OR, 22.5 [95% CI, 6.77–74.7]).
Haptoglobin in Discriminating Between Pneumonia and Malaria-
Associated Respiratory Distress in Gambian Children
Lpc-2 concentrations in children with pneumonia did not differ
signiﬁcantly from those in children with severe malaria and respi-
ratory distress (Figure 3A). We reasoned that a marker of hemo-
lysis such as haptoglobin could discriminate respiratory distress
Figure 1. Diagnostic performanceof clinical andmolecularmarkers to predict
severe pneumonia (vs nonsevere pneumonia) in Gambian children. Only clin-
ical features that were not used to distinguish the 2 groups were introduced
in the model (see Methods). Odds ratios (with 95% conﬁdence intervals
[CIs]) indicate odds of severe pneumonia for cutoff values with the highest
sensitivity and speciﬁcity. Abbreviations: CRP, C-reactive protein; Lpc-2, lip-
ocalin 2; NPV, negative predictive value; PPV, positive predictive value.
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caused by pneumonia from that caused by severe malaria because
haptoglobin levels increase with pneumonia severity and decrease
with malaria severity owing to erythrocyte destruction. The medi-
an (interquartile range) plasma haptoglobin concentration in
children with severe malaria and respiratory distress (10 406
[5267–38 597] ng/mL) was 2 orders of magnitude lower than
that in children with severe pneumonia (2 618 150 [1 800 000–
4 400 000] ng/mL [P < .001]; Supplementary Figure 7). The
sensitivity and speciﬁcity of haptoglobin (>1.1 mg/mL) in dis-
criminating respiratory distress caused by pneumonia from that
caused bymalariawere 92.8% and 99.2%, respectively (Figure 3B).
Children with probable bacterial pneumonia presented with the
highest concentrations of haptoglobin and Lpc-2 (Supplementary
Figure 3C). The combination of Lpc-2 and haptoglobin were ef-
fective in discriminating between pneumonia and severe malaria
with respiratory distress (Figure 3C and 3D). Only 2 of 307 pa-
tients (0.65%) presented with the hemoglobin S mutation of the
β-globin chain (SS genotype). The haptoglobin concentrations
did not differ signiﬁcantly between patients with AS or SS geno-
type and those with AA phenotype.
Lpc-2 and Haptoglobin in Discriminating Between Pneumonia
and Malaria-Associated Respiratory Distress in Kenyan Children
The diagnostic performance of Lpc-2 and haptoglobin in dis-
criminating respiratory distress caused by pneumonia or malar-
ia was evaluated in an independent population of 293 Kenyan
children (Table 5). The same cutoff values derived from the
Gambian data set were applied (Figure 3D). In children admit-
ted to the hospital who had a plasma haptoglobin concentration
>1.1 mg/mL, respiratory distress was 14.8 times more likely to
be caused by pneumonia than by malaria (OR, 14.8 [95% CI,
7.05–31.2]) . The diagnostic performance based on sensitivity
and speciﬁcity was high but expectedly lower than that observed
in Gambian children (AUC, 0.82 [95% CI, .73–.91]). The pro-
portion of children with severe malaria and a high haptoglobin
concentration (11 of 41 [27%]) was the major difference ob-
served between the Kenyan and the Gambian study. We ob-
served a bimodal distribution in haptoglobin concentrations
(above and below 5 × 106 ng/mL) in children with malaria
and respiratory distress and in children with both pneumonia
and malaria (Supplementary Figure 8).
The odds of a positive bacterial culture with a signiﬁcant bac-
terial isolate were signiﬁcantly higher in children with higher
plasma concentrations of Lpc-2 (OR, 5.62 [95% CI, 1.60–
19.6]). However, the diagnostic performance of Lpc-2 in pre-
dicting bacteremia was lower than in Gambian children
(AUC, 0.67 [95% CI, .54–.79]). In Kenyan children, nutritional
status, measured with the height-for-age z score and weight for
age, was inversely correlated with Lpc-2 concentration
(r =−0.13 [P = .02] and r = −0.12 [P = .03]). These differences
were not observed in Gambian children. We therefore reasoned
that differences in theproportionofmalnourished children in the
Figure 2. Diagnostic performance of lipocalin 2 (Lpc-2), von Willebrand factor (vWF) and C-reactive protein (CRP) in predicting probable bacterial infection.
Abbreviations: AUC, area under the receiver operating characteristic curve; CI, conﬁdence interval; LR, likelihood ratio; NPV, negative predictive value; PPV,
positive predictive value; ROC, receiving operating characteristic.
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Kenyan and Gambian populations may account for differences
in the diagnostic performance of Lpc-2. Indeed, the proportion
of children with stunting (measured with the height-for-age
z score) was higher in Kenyan children than in Gambian chil-
dren. The height-for-age z score (but not other measures of
nutritional status) and the presence of oral candidiasis were in-
dependently associated with bacteremia. The diagnostic perfor-
mance of Lpc-2 in predicting blood stream infection increased
to an AUC of 78.7% (95% CI, 60%–86%) after adjustment for
these 2 variables (Supplementary Figure 10). The human im-
munodeﬁciency virus (HIV) status was available for 163 of
293 patients (55.6%) and was positive in 30 patients (18.4%).
Of 12 patients with oral candidiasis, 7 were HIV negative
(58.3%). HIV was not associated with blood stream infection
in the population studied (OR, 1.53 [95% CI, .38–6.03]). The
diagnostic performance of Lpc-2 in predicting bacteremia was
higher in younger children (aged <13.9 months) after adjust-
ment for stunting (AUC, 86%), whereas haptoglobin performed
better in older children (>13.9 months) regardless of nutritional
status (Supplementary Figure 9).
DISCUSSION
This study shows that Lpc-2 is a biomarker associated with se-
vere pneumonia, speciﬁcally with blood culture positivity and
pneumonia designated as being of probable bacterial origin
based on radiological and other criteria. Furthermore, the
Figure 3. Discrimination between pneumonia and malaria-associated respiratory distress in Gambian children. A, Plasma concentration of lipocalin 2
(Lpc-2) in children with different syndromes of respiratory distress and controls. Gray shaded area indicates subanalysis of cases deﬁned as probable bac-
terial or probable nonbacterial pneumonia. B, Distribution of cases of respiratory distress based on plasma levels of Lpc-2 and haptoglobin. C, Diagnostic
performance (receiving operating characteristic curve) of haptoglobin in discriminating between respiratory distress caused by pneumonia and severe ma-
laria with respiratory distress. D, Validation of diagnostic performance in an independent population of Kenyan children. *P < .0001; Abbreviations: NS,
nonsigniﬁcant; NSP, nonsevere pneumonia; RD, respiratory distress; SM, severe malaria; SP, severe pneumonia.
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combination of Lpc-2 with haptoglobin discriminates between
pneumonia and malaria-associated respiratory distress.
To reduce the number of deaths caused by pneumonia, early
diagnosis is critical for pneumonia cases due to bacterial infec-
tion or likely to become severe, so appropriate treatment can be
administered promptly. However, the diagnosis of bacterial
pneumonia is usually compromised by the lack of speciﬁcity
of respiratory symptoms, which are commonly shared with
other conditions that cause respiratory distress in children,
many associated with high case fatality rates. In sub-Saharan
Africa P. falciparum malaria and bacterial blood stream infec-
tions are frequent causes of respiratory distress in children
and possibly pathogenically linked [20]. For a biomarker to
be helpful in this clinical context, its diagnostic performance
has to be superior to clinical examination, and its speciﬁcity
must be sufﬁcient to guide clinical management.
The WHO deﬁnition of pneumonia severity used in our
study is an operational clinical algorithm rather than a “gold
standard.” This deﬁnition aims to reduce mortality by
improving referral practices and thus prioritizes sensitivity
over speciﬁcity. The WHO has recently proposed a more specif-
ic deﬁnition [21]. The starting hypothesis of our study was that
the addition of molecular markers could increase the speciﬁcity
of the clinical deﬁnition of severe pneumonia. In this context,
we have reported 3 potential plasma biomarkers that alone or
in association with clinical features could be used to improve
clinical management by identifying pneumonia with high dis-
ease severity or probable bacterial etiology.
Our results indicate that CRP and Lpc-2 can correctly distin-
guish most patients with severe pneumonia from those with
nonsevere pneumonia and probable bacterial from probable
nonbacterial causes. The sensitivity of these markers combined
increased to 94.7% when the analysis was performed exclusively
in children with pneumonia recruited during the dry season.
The speciﬁcity of this panel of markers decreased from 82%
to 77% when the analysis was performed in children enrolled
during the rainy season (Supplementary Figure 4). Owing to
the high seasonality of malaria transmission in The Gambia
Table 1. Demographic and Clinical Characteristics of the Study Participants by Outcome Group
Characteristic
Pneumonia Severity
Control (n = 186) Nonsevere (n = 96) Severe (n = 76) Very Severe (n = 32)
P
Valuea
Age, median (IQR), mo 15 (8–24) 15 (8–24) 15 (8–24) 12 (6–17) .10
Male sex, % 54.4 54.7 54.0 50.9 .95
Weight-for-age z score, mean
(95% CI)
−0.93 (−1.01 to −0.86) −1.26 (−1.38 to −1.13) −1.46 (−1.59 to −1.32) −1.41 (−1.79 to −1.03) <.001
Respiratory rate, mean (SD),
respirations/min
34 (6.66) 57 (10.1) 64 (12.1) 69 (14.0) <.001
Oxygen saturation, mean (SD), % 98.3 (1.59) 96.5 (1.81) 95.2 (3.09) 84.6 (7.56) <.001
Positive bacterial culture, No. (%) . . . 6 (6.25) 3 (3.95) 2 (6.25) .17
Abbreviations: CI, confidence interval; IQR, interquartile range; SD, standard deviation.
a P values were obtained using Kruskal-Wallis or χ2 test for quantitative or discrete variables, respectively.
Table 2. Molecular Marker Concentrations by Outcome Group
Molecular Marker
Pneumonia Severity
Control Mild Severe Very Severe P Valuea
Median concentration (IQR) [No.]
Lpc-2, ng/mL 59.8 (44.3–78.4) [174] 92.0 (51.6–144) [77] 152 (87.6–283) [73] 224 (139–455) [32] <.001
Haptoglobin, mg/mL 1.22 (0.8–1.94) [160] 1.9 (1.2–2.8) [79] 2.6 (1.8–4.4) [76] 3.8 (2.5–4.9) [32] <.001
vWF, mU/mLb 731 (459–1082) [96] 757 (480–1361) [67] 1260 (751–1725) [68] 1955 (1337–2459) [32] <.001
CRP, µg/mLb 6.19 (4.78–20.1) [55] 93.1 (17.9–227) [77] 258 (184–332) [65] 116 (63–230) [24] <.001
Abbreviations: CRP, C-reactive protein; IQR, interquartile range; Lpc-2, lipocalin 2; vWF, von Willebrand factor.
a P values are derived from an ordinal univariate logistic regression model wherein the dependent variable (disease severity) is coded as 0–3 (from control [0] to very
severe [3]) and the independent variables are the concentrations of the biomarkers. Differences in the number of samples tested for different biomarkers depended
on sample availability and the number of tests required to measure concentration within linear range of the enzyme-linked immunosorbent assay standard.
b The sample volume available for enzyme immunoassay measurements was limited, and Lpc-2 and haptoglobin were prioritized over vWF or CRP. This accounts for
the discrepancies observed in the number of samples tested for CRP and vWF.
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and the fact that both CRP and Lpc-2 have been shown to in-
crease in children with malaria [22, 23], it is plausible that this
increase in sensitivity and speciﬁcity is explained by the low
number of malaria infections during the dry season. This in-
crease in diagnostic speciﬁcity is likely to reduce but not
completely remove the number of false-positive cases burden-
ing busy health services. Similarly, our panel of biomarkers per-
formed well against the more recent deﬁnition for severity
proposed by the WHO in 2013 (Supplementary Figure 5).
Here we report that Lpc-2 is associated with blood culture pos-
itivity. This is particularly important because clinical features did
not identify children with a positive bacterial blood culture. We
did not conﬁrm ﬁndings from some previous studies reporting
an association between bacterial infection and the clinical signs
of respiratory distress or high temperature (Supplementary
Table 6) [24–28].To our knowledge, we are also the ﬁrst to report
that Lpc-2 is associated with pneumonia of probable bacterial or-
igin, deﬁned by the presence of consolidation on the chest radio-
graph or a positive blood culture. This was true for both primary
bacterial and nonbacterial pneumonia deﬁnitions. The associa-
tion of Lpc-2 with positive blood cultures and pneumonia of
probable bacterial origin is biologically plausible and clinically
important. We also observed that the association of Lpc-2 and
bacteremia in Kenyan children, although signiﬁcant, was partially
compromised by the patient’s nutritional status. This observation
may be explained, at least in part, by the reduced ability of pa-
tients with chronic malnutrition to generate an effective immune
response to infection. This limitation may be important in the
design of prospective studies, and different cutoff values may
be required for populations with severe stunting.
The role of Lpc-2 in innate defense against bacterial infection
is well established. The transcription of the Lpc-2 gene has been
shown to be up-regulated in activated macrophages through Toll-
like receptor 4 ligation and to interfere with bacterial iron uptake
[29, 30]. More importantly, Lpc-2 transcription is increased by
65-fold in the nasal mucosa of mice in response to S. pneumoniae
and Haemophilus inﬂuenzae colonization [31].
In resource-limited settings where laboratory facilities and ra-
diology are rarely available to help diagnose bacterial pneumo-
nia cases, molecular markers such as Lpc-2 could be developed
into a point-of-care diagnostic tool to target cases that require
Table 3. Diagnostic Performance of Clinical Features and
Molecular Markers Associated With a Risk of Severe or Very
Severe Pneumonia (vs Nonsevere Pneumonia)
Likelihood Ratioa
Clinical Feature
Children,
No. AUC (95% CI) Positive Negative
Respiratory rateb 204 0.76 (.70–.83) . . . . . .
Cracklesb 204 0.72 (.66–.77) . . . . . .
Heart rate 204 0.68 (.61–.75) . . . . . .
Pallor 204 0.57 (.52–.61) . . . . . .
Molecular marker
Lpc-2b 182 0.71 (.64–.79) 2.39 0.40
CRPb 166 0.68 (.60–.76) 1.66 0.53
vWFb 167 0.70 (.62–.78) 2.16 0.46
Abbreviations: AUC, area under the receiver operating characteristic curve; CI,
confidence interval; CRP, C-reactive protein; Lpc-2, lipocalin 2; vWF, von
Willebrand factor.
a The positive and negative likelihood ratios have been calculated for the
biomarker concentrations with the highest sensitivity and specificity for
predicting severe pneumonia (Lpc-2, 118 ng/mL; CRP, 157 mg/mL; and
vWF, 648 mU/mL).
b Variables independently associatedwith outcome in the multivariate models.
Table 4. Population Description of Patients With Pneumonia of Probable Bacterial or Probable Viral Etiology
Characteristic
Pneumonia
Probable Non-bacterial (n = 49) Probable Bacterial (n = 54) P Valuea
Age, mean (SD), mo 19 (10.5) 17.4 (11.6) .14
Male sex, % 50% 51% .90
Weight-for-age z score, mean (SD) −1.03 (1.10) −1.37 (1.21) .24
Respiratory rate, mean (SD), respirations/min 57.0 (12.0) 62.6 (9.8) .007
Oxygen saturation, mean (SD), % 96.3 (2.64) 92.84 (7.09) <.01
WBC count, mean (SD), ×109/L 10.1 (6.42) 23.7 (10.6) <.01
Hemoglobin, mean (SD), g/dL 10.3 (1.53) 8.65 (1.74) <.01
Molecular marker concentration, median (IQR) [No.]
Lpc-2, ng/mL [42] 81.7 (45.7–109) [45] 282 (155–365) <.001
CRP, µg/mL [41] 175 (182–278) [47] 283 (142–350) <.001
vWF, mU/mL [34] 810 (647–1201) [45] 1514 (1205–2036) <.001
Abbreviations: CRP, C-reactive protein; IQR, interquartile range; Lpc-2, lipocalin 2; SD, standard deviation; vWF, von Willebrand factor; WBC, white blood cell.
a P values were obtained using Mann-Whitney or χ2 test for quantitative or discrete variables, respectively.
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antibiotic treatment. Indeed, Lpc-2 concentrations could be
used to stop antibiotic treatment in patients who show a
quick clinical recovery. Similarly, for acute respiratory infections
at the community level, Lpc-2 could be used to determine the
indications for and guide the timing of antibiotic treatment
[32–35]. The proteomic workﬂow used in this study could not
identify proteins at concentrations below the mid–nanogram-
per-milliliter range [14], such as tumor necrosis factor, interleu-
kin 6, and procalcitonin, previously shown to be associated with
blood stream infection [36].
We found that haptoglobin in combination with Lpc-2 was
remarkably effective in discriminating between pneumonia
and malaria in children with respiratory distress. Two major
reasons account for this observation. Firstly, hemolysis is a
major feature of acute malaria infection but not pneumonia
[37]. During active hemolysis, free hemoglobin binds to hapto-
globin, leading to a rapid depletion of this molecule from plas-
ma [38]. Secondly, the concentration of plasma haptoglobin
increased with disease severity in patients with Pneumonia.
Point-of-care diagnostics can help in making rapid clinical
decisions in developing countries. Clinical efﬁcacy and cost-
effectiveness analysis studies are required to estimate the poten-
tial impact of these novel tools [39]. In malaria-endemic areas,
the combination of Lpc-2 with haptoglobin should be prospec-
tively evaluated for use in guiding the clinical management of
children with respiratory distress.
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